Dernières nouvelles pour Leap Therapeutics (NASDAQ:LPTX) Stock

Leap Therapeutics

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Leap Therapeutics Inc

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 20 years by 6.03% on an annualized basis producing an average annual return of 14.45%. Currently, Eli Lilly has a market capitalization of $740.34 billion. 
Buying $100 In LLY: If an investor had bought $100 of LLY stock 20 years ago, it would be worth $1,476.91 today based on a price of $823.23 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738280753_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Wells Fargo analyst Donald Fandetti maintains AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>) with a Overweight and lowers the price target from $12 to $11.

Price Target

Analyst Ratings

AGNC

Wells Fargo Maintains Overweight on AGNC Investment, Lowers Price Target to $11

Billionaire Jeff Bezos appears to have a major conflict of interest on his hands with a newspaper he owns trying to get records from another<a href="https://www.benzinga.com/news/21/04/20675447/5-things-you-might-not-know-about-jeff-bezos"> company he founded.</a>
What Happened: While he's <a href="https://www.benzinga.com/news/21/07/21849808/jeff-bezos-is-officially-no-longer-the-amazon-ceo">no longer the CEO</a> of Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Bezos remains a shareholder and the executive chairman of the company.
This means that a lawsuit filed by Amazon against the Washington Post, which Bezos owns, now has the billionaire on both sides of the legal fight.
The Washington Post is trying to obtain records related to Amazon's Project Kuiper satellite business, <a href="https://www.hollywoodreporter.com/business/business-news/jeff-bezos-amazon-sues-block-records-requests-washington-post-1236121933/">according </a>to The Hollywood Reporter.
Amazon is fighting back and has sued to block the records request as the e-commerce company states releasing the information could be harmful as it contains trade secrets.
The report says items requested by the news outlet include inspection records, investigation notes and complaints related to visits to the company by the Washington Department of Labor and Industries.
Amazon says the records contain proprietary satellite designs and other information that could give competitors "a competitive edge."
Amazon has not sued the newspaper directly, instead filing a lawsuit against a Washington state agency that agreed to disclose the records. The company is not seeking to block the release of all of the requested records, only a small portion that it believes contains trade secrets.
You may not be a billionaire like Jeff Bezos, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/25/01/43201590/benzinga-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-2">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: The news of the battle by The Washington Post against Amazon comes as the newspaper faces public pushback after <a href="https://www.benzinga.com/general/politics/24/10/41557083/jeff-bezos-ends-washington-posts-36-year-tradition-of-endorsements-leaving-staff-roiled">not endorsing a candidate </a>for president for the first time since 1988.
The decision was said to have been made by Bezos, who bought the newspaper in 2013. The move led to the exit of several newspaper workers and saw around 250,000 subscribers cancel their subscriptions as a result.
The battle between The Washington Post and Amazon and the outcome could become a storyline for Bezos and whether or not billionaires should own news outlets.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/09/41107170/jeff-bezos-used-this-method-to-get-true-opinions-from-employees-amazon-founder-says-youre-the-b">Jeff Bezos Used This Method To Get True Opinions From Employees: Amazon Founder Says &#8216;You&#8217;re The Boss&#8217;</a></li>
</ul>
Photos: Shutterstock

SPACE

Media

AMZN

Bezos Vs. Bezos: Amazon Files Lawsuit Related To Washington Post In Major Conflict Of Interest For Billionaire

Wells Fargo analyst Larry Biegelsen maintains NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) with a Overweight and raises the price target from $13 to $17.

NPCE

Wells Fargo Maintains Overweight on NeuroPace, Raises Price Target to $17

Wells Fargo analyst Ike Boruchow maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Equal-Weight and lowers the price target from $45 to $40.

VSCO

Wells Fargo Maintains Equal-Weight on Victoria's Secret, Lowers Price Target to $40

Wells Fargo analyst Matthew Akers maintains RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) with a Overweight and raises the price target from $151 to $156.

Wells Fargo Maintains Overweight on RTX, Raises Price Target to $156

Wells Fargo analyst Matthew Akers maintains Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) with a Equal-Weight and lowers the price target from $500 to $497.

Wells Fargo Maintains Equal-Weight on Lockheed Martin, Lowers Price Target to $497

Wells Fargo analyst Derek Archila maintains Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) with a Equal-Weight and lowers the price target from $8 to $6.

ZNTL

Wells Fargo Maintains Equal-Weight on Zentalis Pharma, Lowers Price Target to $6

Wells Fargo analyst Zachary Fadem maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Equal-Weight and raises the price target from $145 to $175.

Wells Fargo Maintains Equal-Weight on Brinker International, Raises Price Target to $175

Wells Fargo analyst David Lantz maintains Monro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNRO#NASDAQ">MNRO</a>) with a Equal-Weight and lowers the price target from $24 to $20.

MNRO

Wells Fargo Maintains Equal-Weight on Monro, Lowers Price Target to $20

Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) has outperformed the market over the past 15 years by 6.96% on an annualized basis producing an average annual return of 19.23%. Currently, Blackstone has a market capitalization of $135.00 billion. 
Buying $1000 In BX: If an investor had bought $1000 of BX stock 15 years ago, it would be worth $13,976.42 today based on a price of $177.82 for BX at the time of writing.
<h3>Blackstone's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738279807_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Wells Fargo analyst Ike Boruchow maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Underweight and raises the price target from $17 to $21.

Wells Fargo Maintains Underweight on VF, Raises Price Target to $21

UBS analyst Alex Kramm maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Neutral and raises the price target from $79 to $89.

NDAQ

UBS Maintains Neutral on Nasdaq, Raises Price Target to $89

UBS analyst Gregg Orrill maintains PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) with a Buy and lowers the price target from $24 to $22.

UBS Maintains Buy on PG&E, Lowers Price Target to $22

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy and lowers the price target from $30 to $27.

TEVA

UBS Maintains Buy on Teva Pharmaceutical Indus, Lowers Price Target to $27

UBS analyst Timothy Arcuri maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Neutral and lowers the price target from $78 to $70.

UBS Maintains Neutral on Western Digital, Lowers Price Target to $70

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk has turned increasingly political in recent years, a move that may have hurt the brand value of the <a href="https://www.benzinga.com/news/global/25/01/43172806/tesla-lost-15-billion-in-brand-value-in-2024-report-says-did-elon-musks-political-push-hurt-ev-giant">electric vehicle company.</a>
While Musk is OK with supporting President Donald Trump and the end of the $7,500 federal tax credit, the billionaire also has his eyes set on a sustainable future.
What Happened: A proposed end to the <a href="https://www.benzinga.com/trading-ideas/25/01/43116755/trumps-plan-to-end-7500-ev-tax-credits-could-be-devastating-for-telsa-rivals-poll-says-could-be-bullish-for-elon-musks-company">$7,500 EV tax credit </a>by Trump is one of the biggest storylines for the electric vehicle sector and Musk is a supporter of making such a change.
Musk and Tesla analysts believe the decision to end the credit would be bad for Tesla in the short term, but ultimately benefit the company in the long term as it would be tougher on competitors.
The Tesla CEO was asked about electric vehicle policies under Trump during the company's<a href="https://www.benzinga.com/news/earnings/25/01/43321103/tesla-q4-earnings-highlights-revenue-miss-eps-miss-ev-updates-automaker-says-2025-will-be-a-seminal-year"> fourth-quarter earnings call.</a>
An analyst asked about plans to reverse the "EV mandate" and potential slowdowns of electric vehicle demand in the U.S. due to regulations.
Musk shied away from the question but did highlight his continued belief on electric vehicles being a big part of the future.
"At this point, I think that sustainable transport is inevitable," Musk said, as shared by <a href="https://insideevs.com/news/749018/musk-q4-call-ev-regulations/">InsideEVs</a>. "I'm highly confident that all transport will be autonomous, electric, including aircraft, and that simply, it can't be stopped."
Musk went on to compare the rise of electric vehicles to the introduction of the internal combustion engine.
"Even if you've been the biggest horse advocate on Earth … like, ‘horses are the way, not these new-fangled automobiles,' you can't stop the advent of the automobile and you can't stop the advent of electric cars. It's going to happen."
The Tesla CEO said the only thing holding back electric vehicles previously was range, which has been solved.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: While investors and analysts wanted to hear about Musk's relationship with Trump, what his role<a href="https://www.benzinga.com/news/global/24/11/41927289/trump-appoints-elon-musk-and-vivek-ramaswamy-to-lead-doge-targeting-bureaucracy-and-65-trillion-federal-spending-we-will-not-go-gently"> at the D.O.G.E. </a>means for his time commitment at Tesla and how Trump's EV policies could shape the industry, the earnings call left many questions unanswered.
Trump has been a vocal critic of electric vehicles and also previously said he would ban autonomous vehicles from U.S. roads, a move that would severely hurt the future growth plan of Tesla and its robotaxis.
New Transportation Secretary Sean Duffy shared in a memo that the previous push by Joe Biden's administration for electric vehicles was "forced" on people.
Musk's comments about the future being all-electric and autonomous go against the commentary of Trump and his administration, which could make the friendship between the billionaire and president an interesting development to watch as Musk will likely have to push for support of autonomous vehicles.
Rivian Automotive CEO RJ Scaringe recently <a href="https://www.benzinga.com/25/01/43279098/rivian-ceo-brushes-off-7500-electric-vehicle-tax-credit-concerns-evs-are-not-a-political-thing">shared a similar commentary</a> of keeping his eyes on the future and ignoring the short-term "speed bumps" created by items like the end of the federal tax credit.
&#8220;I started the company with the view of making highly compelling products, and none of my decision to start Rivian had anything to do with what the policy was going to look like,&#8221; Scaringe said.
Scaringe said that the potential elimination of the $7,500 tax credit would be &#8220;equally applied to all,&#8221; which could mean a level playing field for all companies in the electric vehicle sector.
&#8220;The future of transportation will be electric.&#8221;
Scaringe said policy revisions like this can&#8217;t slow down the long-term trend of electric vehicle growth and the necessity of having more electric vehicles on the road.
&#8220;This is not a political thing. It&#8217;s not like the left wants to move to electrification. It&#8217;s that the future of transportation will be electric.&#8221;
Watch the Tesla fourth-quarter earnings call with Musk below. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43347509/tesla-stock-analysts-highlight-fsd-robotaxis-new-vehicles-for-growth-elon-has-never-sounded-so-bullish">Tesla Analysts Highlight FSD, Robotaxis, New Vehicles For Growth: &#8216;Elon Has Never Sounded So Bullish&#8217;</a></li>
</ul>
Photo: Shutterstock
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534; WATCH LIVE: Tesla Q4 2024 Earnings Call &#x7C; $TSLA" width="500" height="281" src="https://www.youtube.com/embed/G2UrBRGrLb0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Earnings

Politics

TSLA

Elon Musk Brushes Aside Concerns On Trump's EV Policies: 'Sustainable Transport Is Inevitable … It Can't Be Stopped'

UBS analyst Karl Keirstead maintains Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Buy and lowers the price target from $525 to $510.

MSFT

UBS Maintains Buy on Microsoft, Lowers Price Target to $510

UBS analyst Jay Sole maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Neutral and raises the price target from $24 to $28.

UBS Maintains Neutral on VF, Raises Price Target to $28

UBS analyst Lloyd Walmsley maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $736 to $786.

UBS Maintains Buy on Meta Platforms, Raises Price Target to $786

Leap Therapeutics (LPTX) announced positive initial data from Part B of the DeFianCe study evaluating sirexatamab in combination with bevacizumab a...

Leap Therapeutics reports initial data from DeFianCe, DisTinGuish studies

Leap scraps late-stage plans for gastric cancer therapy after mid-stage setback

Leap Therapeutics: 2 Cancer Trials Disappoint, But There Is A Silver Lining

Baird downgraded Leap Therapeutics (LPTX) to Neutral from Outperform with a price target of $1.25, down from $9, after after the company announced ...

Leap Therapeutics downgraded to Neutral from Outperform at Baird

H.C. Wainwright downgraded Leap Therapeutics (LPTX) to Neutral from Buy without a price target after the company presented clinical data updates fr...

Leap Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Leap Therapeutics (LPTX – Research Report) and Imm...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Leap Therapeutics (LPTX) and Immunovant (IMVT)

Piper Sandler lowered the firm's price target on Leap Therapeutics (LPTX) to $3 from $15 and keeps an Overweight rating on the shares. The firm not...

Leap Therapeutics price target lowered to $3 from $15 at Piper Sandler

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Apple downgraded, Rivian initiated: Wall Street's top analyst calls

Leap Therapeutics cut to Neutral at Baird after mid-stage trial setback

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Comments

Leap Therapeutics

Actualités

Dernières nouvelles pour Leap Therapeutics (NASDAQ:LPTX) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL